Research graph
References from HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America. Local targets link to admitted publications; unresolved targets remain external evidence.
HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America
10.1016/j.cardfail.2025.07.007 · 2026 · External reference
Lifetime risk of heart failure among participants in the Framingham study
10.1016/j.jacc.2021.10.043 · 2022 · External reference
Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
10.1161/circulationaha.117.031622 · 2018 · External reference
Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years
10.1093/eurheartj/ehae868 · 2025 · External reference
Hypertension, Obesity, Diabetes, and Heart Failure-Free Survival: The Cardiovascular Disease Lifetime Risk Pooling Project
10.1016/j.jchf.2016.08.001 · 2016 · External reference
Temporal trends in heart failure incidence among medicare beneficiaries across risk factor strata, 2011 to 2016
10.1001/jamanetworkopen.2020.22190 · 2020 · External reference
Trends in hospitalizations and survival of acute decompensated heart failure in four US communities (2005-2014): ARIC study community surveillance
10.1161/circulationaha.117.027551 · 2018 · External reference
Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction
10.1016/j.jchf.2018.03.006 · 2018 · External reference
A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010
10.1001/jamainternmed.2015.0924 · 2015 · External reference
Contemporary epidemiology of heart failure in fee-for-service Medicare beneficiaries across healthcare settings
10.1161/circheartfailure.117.004402 · 2017 · External reference
Cardiovascular disease burden and outcomes among American Indian and Alaska Native Medicare beneficiaries
10.1001/jamanetworkopen.2023.34923 · 2023 · External reference
Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis
10.1186/s12889-022-13639-2 · 2022 · External reference
Association of Rurality With Risk of Heart Failure
10.1001/jamacardio.2022.5211 · 2023 · External reference
Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project
10.1016/j.jacc.2013.01.022 · 2013 · External reference
Age dependent associations of risk factors with heart failure: pooled population based cohort study
10.1136/bmj.n461 · 2021 · External reference
Long-term trends in the incidence of and survival with heart failure
10.1056/nejmoa020265 · 2002 · External reference
Trends in heart failure incidence and survival in a community-based population
10.1001/jama.292.3.344 · 2004 · External reference
Sex Differences in Age of Onset of Premature Cardiovascular Disease and Subtypes: The Coronary Artery Risk Development in Young Adults Study
10.1161/jaha.125.044922 · 2026 · External reference
Race and ethnicity in heart failure: JACC focus seminar 8/9
10.1016/j.jacc.2021.06.058 · 2021 · External reference
Heart Failure Incidence and Mortality in the Southern Community Cohort Study
10.1161/circheartfailure.116.003553 · 2017 · External reference
Trends in the Prevalence, Associated Risk Factors, and Health Burden of Heart Failure in the United States, 1988 to 2023
10.1016/j.jacc.2025.09.1503 · 2025 · External reference
Forecasting the burden of cardiovascular disease and stroke in the United States through 2050-prevalence of risk factors and disease: a presidential advisory from the American Heart Association
10.1161/cir.0000000000001256 · 2024 · External reference
2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
10.1161/cir.0000000000001412 · 2026 · External reference
Trends in the prevalence of self-reported heart failure by race/ethnicity and age from 2001 to 2016
10.1001/jamacardio.2020.3654 · 2020 · External reference
2025 Heart disease and stroke statistics: a report of US and global data From the American Heart Association
10.1161/cir.0000000000001303 · 2025 · External reference
Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990-2019
10.1093/ehjqcco/qcac088 · 2023 · External reference
Prevalence and mortality rate of heart failure across demographic groups in the United States: 2001–2020
2025 · External reference
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study
10.1161/circulationaha.119.043628 · 2020 · External reference
Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure
10.1016/j.jacc.2025.06.046 · 2025 · External reference
The epidemiology, clinical characteristics, and burden of heart failure with or without obesity in US patients
10.1080/03007995.2025.2535464 · 2025 · External reference
Trends in hospital admissions for systolic and diastolic heart failure in the United States between 2004 and 2017
10.1016/j.amjcard.2022.01.047 · 2022 · External reference
10.1002/ejhf.2115
10.1002/ejhf.2115 · 2021 · External reference
2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2021.12.012 · 2022 · External reference
Recognition of the large ambulatory C2D stage of advanced heart failure-a call to action
10.1001/jamacardio.2024.5328 · 2025 · External reference
Prevalence of American Heart Association heart failure stages in Black and White young and middle-aged adults: the CARDIA study
10.1161/circheartfailure.118.005730 · 2019 · External reference
Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community
10.1016/j.jchf.2016.05.001 · 2016 · External reference
Heart failure stages among older adults in the community: the atherosclerosis risk in communities study
10.1161/circulationaha.116.023361 · 2017 · External reference
Reclassification of pre-heart failure stages using cardiac biomarkers: the ARIC study
10.1016/j.jchf.2022.12.005 · 2023 · External reference
Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort
10.1016/j.jacc.2023.04.007 · 2023 · External reference
Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community
10.1161/circulationaha.106.666818 · 2007 · External reference
Advanced heart failure epidemiology and outcomes: a population-based study
10.1016/j.jchf.2021.05.009 · 2021 · External reference
Ambulatory Stage C2D Heart Failure Definitions and Current Therapeutic Approaches
2026 · External reference
Differentiation Between Worsening Heart Failure and Decompensated Heart Failure
10.1016/j.jchf.2023.06.001 · 2023 · External reference
Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week
10.1016/j.jacc.2022.11.023 · 2023 · External reference
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR
10.1016/j.jacc.2025.08.051 · 2025 · External reference
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)
10.1161/circulationaha.115.020729 · 2016 · External reference
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
10.1056/nejmoa2206286 · 2022 · External reference
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
10.1001/jamacardio.2025.0016 · 2025 · External reference
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF
10.1161/circulationaha.120.047480 · 2020 · External reference
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
10.1161/circulationaha.123.066506 · 2023 · External reference
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
10.1161/cir.0000000000001184 · 2023 · External reference
US State-Level Prevalence of Adult Obesity by Race and Ethnicity From 1990 to 2022 and Forecasted to 2035
10.1001/jama.2025.26817 · 2026 · External reference
Sex Differences in Cardiovascular-Kidney-Metabolic Syndrome: 30-Year US Trends and Mortality Risks-Brief Report
10.1161/atvbaha.124.321629 · 2025 · External reference
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
10.1001/jamacardio.2023.3241 · 2023 · External reference
Association between cardiometabolic comorbidity burden and outcomes in heart failure
10.1161/jaha.124.036985 · 2025 · External reference
Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF
10.1002/ejhf.3304 · 2024 · External reference
Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. veterans with heart failure
10.1002/ejhf.3210 · 2024 · External reference
Outcomes of KDIGO-Defined CKD in U.S. veterans With HFpEF, HFmrEF, and HFrEF
10.1016/j.jchf.2024.11.007 · 2025 · External reference
2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
10.1161/cir.0000000000001412 · 2026 · External reference
Unresolved reference
External reference
Unresolved reference
2024 · External reference
Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study
10.1016/s2214-109x(17)30196-1 · 2017 · External reference
Survival of Patients with Chronic Heart Failure in the Community: A Systematic Review and Meta-Analysis
10.1002/ejhf.1594 · 2019 · External reference
HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America
2025 · External reference
Correction to: Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study
10.1016/s2214-109x(20)30294-1 · 2020 · External reference
Where Adults With Heart Failure Die: Insights From the CDC-WONDER Database
2025 · External reference
Contemporary Trends in Heart Failure Mortality: The Pandemic Ended, the Epidemic Continues
10.1016/j.jchf.2026.103066 · 2026 · External reference
Reversals in the Decline of Heart Failure Mortality in the US, 1999 to 2021
10.1001/jamacardio.2024.0615 · 2024 · External reference
Heart failure quality of care and in-hospital outcomes during the COVID -19 pandemic: findings from the Get With The Guidelines-Heart Failure registry
10.1002/ejhf.2484 · 2022 · External reference
Prevalence and mortality rate of heart failure across demographic groups in the United States: 2001–2020
2025 · External reference
National trends in heart failure mortality in men and women, United Kingdom, 2000–2017
10.1002/ejhf.1996 · 2021 · External reference
Reversed sex disparities in heart failure mortality in Spain, 2000–2023: a population-based analysis of older adults
10.3389/fpubh.2025.1645351 · 2025 · External reference
Excess Cardiovascular Mortality Among Black Americans 2000-2022
10.1016/j.jacc.2024.06.004 · 2024 · External reference
Implementation science to achieve equity in heart failure care: a scientific statement from the American Heart Association
10.1161/cir.0000000000001231 · 2024 · External reference
Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients
10.1161/circulationaha.120.052254 · 2021 · External reference
Evaluation of Racial and Ethnic Disparities in Cardiac Transplantation
10.1161/jaha.120.021067 · 2021 · External reference
OPTN/SRTR 2023 Annual Data Report: Heart
10.1016/j.ajt.2025.01.024 · 2025 · External reference
Surveys & Programs
2026 · External reference
Changes in the Geographic Patterns of Heart Disease Mortality in the United States: 1973 to 2010
10.1161/circulationaha.115.018663 · 2016 · External reference
Unresolved reference
2026 · External reference
Geographic variation in trends and disparities in heart failure mortality in the United States, 1999 to 2017
10.1161/jaha.120.020541 · 2021 · External reference
Trends in obesity and heart failure-related mortality in middle-aged and young adult populations of the united states, 1999–2022
10.1186/s12872-025-05029-4 · 2025 · External reference
Regional Variation in the Association of Poverty and Heart Failure Mortality in the 3135 Counties of the United States
10.1161/jaha.119.012422 · 2019 · External reference
Which Definition of Rurality Should I Use?: The Relative Performance of 8 Federal Rural Definitions in Identifying Rural-Urban Disparities
10.1097/mlr.0000000000001612 · 2021 · External reference
Unresolved reference
2025 · External reference
What Is Rural? Challenges And Implications Of Definitions That Inadequately Encompass Rural People And Places
10.1377/hlthaff.2019.00910 · 2019 · External reference
Rural–urban disparities in mortality of patients with acute myocardial infarction and heart failure: a systematic review and meta-analysis
10.1093/eurjpc/zwae351 · 2025 · External reference
Trends in heart failure-related cardiovascular mortality in rural versus urban United States counties, 2011–2018: A cross-sectional study
10.1371/journal.pone.0246813 · 2021 · External reference
The role of comorbidities, medications, and social determinants of health in understanding urban-rural outcome differences among patients with heart failure
10.1111/jrh.12803 · 2024 · External reference
Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019
10.1016/j.jchf.2022.06.012 · 2022 · External reference
Rural-Urban Disparities in Heart Failure and Acute Myocardial Infarction Hospitalizations
10.1016/j.amjcard.2022.04.014 · 2022 · External reference
Impact of Rural Hospital Closures on Health-Care Access
10.1016/j.jss.2020.08.055 · 2021 · External reference
Racial and Ethnic Disparities in Referral to Outpatient Heart Failure Management at Hospital Discharge: A Get With The Guidelines Analysis
2025 · External reference
Quality of Care and Patient Outcomes in Critical Access Rural Hospitals
10.1001/jama.2011.902 · 2011 · External reference
Medicaid Expansion and 30-Day Mortality After Heart Failure Hospitalization: A Nationwide Study
10.1002/clc.70240 · 2025 · External reference
Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes
10.1016/j.jacc.2017.08.074 · 2017 · External reference
Trends in Heart Failure Mortality in Sweden Between 1997 and 2022
10.1002/ejhf.3506 · 2025 · External reference
Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban US hospitals: the Get With the Guidelines-Heart Failure Registry
10.1001/jamacardio.2023.0241 · 2023 · External reference
Five-Year Mortality of Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in a 4880 Chinese Cohort
10.1002/ehf2.13921 · 2022 · External reference
Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study
10.1093/eurheartj/ehy005 · 2018 · External reference
Heart failure with mid-range or mildly reduced ejection fraction
10.1038/s41569-021-00605-5 · 2022 · External reference
Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry
10.1002/ejhf.3230 · 2024 · External reference
Left ventricular ejection fraction and the future of heart failure phenotyping
10.1016/j.jchf.2023.11.005 · 2024 · External reference
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines
10.1016/j.jacc.2025.06.036 · 2025 · External reference
Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the Valsartan heart failure trial
10.1161/circheartfailure.116.003123 · 2016 · External reference
Readmission Following Both Cardiac and Non-Cardiac Acute Dyspnoea is Associated with a Striking Risk of Death
10.1002/ehf2.13369 · 2021 · External reference
Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure: The REVEAL-HF Randomized Clinical Trial
10.1001/jamacardio.2022.2496 · 2022 · External reference
Medium and Long-Term Cause-Specific Mortality Following First-Ever Heart Failure Hospitalisation in New Zealand
10.1016/j.hlc.2024.05.009 · 2024 · External reference
Trends in mortality after incident hospitalization for heart failure among Medicare beneficiaries
10.1001/jamanetworkopen.2024.28964 · 2024 · External reference
Cause-specific health care costs following hospitalization for heart failure and cost offset with SGLT2i therapy
10.1016/j.jchf.2024.04.003 · 2024 · External reference
Quality of care and clinical outcomes for patients with heart failure at hospitals caring for a high proportion of black adults: Get With the Guidelines–Heart Failure Registry
10.1001/jamacardio.2023.0695 · 2023 · External reference
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk Score
10.1161/jaha.124.037973 · 2025 · External reference
Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the change the management of patients with heart failure registry
2021 · External reference
One-year mortality after intensification of outpatient diuretic therapy
10.1161/jaha.119.016010 · 2020 · External reference
Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems
2025 · External reference
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)
10.1002/ejhf.2271 · 2021 · External reference
National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2021
2025 · External reference
National Differences in Trends for Heart Failure Hospitalizations by Sex and Race/Ethnicity
2025 · External reference
National trends in heart failure hospitalizations and readmissions from 2010 to 2017
10.1001/jamacardio.2020.7472 · 2021 · External reference
Cardiovascular Statistics in the United States, 2026
10.1016/j.jacc.2025.12.027 · 2026 · External reference
Trends in HF hospitalizations among young adults in the united States from 2004 to 2018
10.1016/j.jchf.2022.01.021 · 2022 · External reference
Trends in heart failure hospitalizations in the US from 2008 to 2018
10.1016/j.cardfail.2021.08.020 · 2022 · External reference
Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018
10.1016/j.ahj.2021.09.009 · 2022 · External reference
Sex differences in long-term heart failure prognosis: a comprehensive meta-analysis
10.1093/eurjpc/zwae256 · 2024 · External reference
Sex disparities in outcomes among hospitalizations for heart failure
10.1038/s41598-024-77109-y · 2024 · External reference
Cardiovascular health in American Indians and Alaska Natives: a scientific statement from the American Heart Association
10.1161/cir.0000000000000773 · 2020 · External reference
Divergent Temporal Trends in Morbidity and Mortality Related to Heart Failure and Atrial Fibrillation: Age, Sex, Race, and Geographic Differences in the United States, 1991-2015
10.1161/jaha.118.010756 · 2019 · External reference
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022
2026 · External reference
Regional Variation in Mortality, Length of Stay, Cost, and Discharge Disposition Among Patients Admitted for Heart Failure in the United States
10.1016/j.amjcard.2017.05.058 · 2017 · External reference
National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008
10.1001/jama.2011.1474 · 2011 · External reference
Geographic Disparities in Heart Failure Hospitalization Rates Among Medicare Beneficiaries
10.1016/j.jacc.2009.10.021 · 2010 · External reference
Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry
10.1161/jaha.120.018696 · 2021 · External reference
Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries
2024 · External reference
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups
2023 · External reference
Potential implications of expanded US food and drug administration labeling for sacubitril/valsartan in the US
10.1001/jamacardio.2021.3651 · 2021 · External reference
Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice
10.1002/ejhf.2778 · 2023 · External reference
Patient-Reported Outcomes in Heart Failure Clinical Trials: Trends, Utilization, and Implications
2025 · External reference
Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments
10.7326/m22-2234 · 2022 · External reference
Patient-Reported Health Status Among Patients With Heart Failure With Improved Ejection Fraction
10.1161/jaha.125.043489 · 2026 · External reference
Predicting Heart Failure Outcomes Using Patient-Reported Health Status
10.1016/j.jacc.2025.03.545 · 2025 · External reference
Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction
10.1001/jamacardio.2021.0939 · 2021 · External reference
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure
10.1016/j.jchf.2018.02.002 · 2018 · External reference
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction
10.1001/jamacardio.2021.0372 · 2021 · External reference
Health Status in Heart Failure and Cancer
2024 · External reference
Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries
10.1161/circulationaha.120.050850 · 2021 · External reference
Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)
10.1016/j.jchf.2022.08.009 · 2023 · External reference
Guideline-directed medical therapy prescribing patterns and in-hospital outcomes among heart failure patients during COVID-19
2024 · External reference
Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines–Heart Failure Registry
10.1001/jamacardio.2023.1266 · 2023 · External reference
Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study
10.1161/jaha.125.044785 · 2026 · External reference
Guideline Directed Medical Therapy Trends in the United States 2023-2025: An Analysis of Three Million Individuals
10.1016/j.cardfail.2026.02.047 · 2026 · External reference
Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction
10.1001/jamacardio.2026.0375 · 2026 · External reference
Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic
2025 · External reference
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
10.1016/j.jchf.2024.03.001 · 2024 · External reference
Sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction
10.1161/circulationaha.123.067489 · 2024 · External reference
Prioritizing Time from Diagnosis to Quadruple Therapy in Heart Failure Care
10.1001/jamacardio.2026.0393 · 2026 · External reference
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure
2025 · External reference
Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
10.1001/jamacardio.2024.4489 · 2025 · External reference
Quantification of Device-Related Event Reports Associated With the CardioMEMS Heart Failure System
2022 · External reference
Transcatheter Mitral Valve Therapy in the United States: A Report from the STS/ACC TVT Registry
10.1016/j.athoracsur.2021.07.030 · 2022 · External reference
Out-of-Hospital 30-Day Mortality After Mitral TEER: Insights From the STS/ACC TVT Registry
10.1016/j.jcin.2025.01.425 · 2025 · External reference
Uptake, Geographic Access, and Outcomes of Transcatheter Mitral Valve Repair in the United States
2025 · External reference
Transcatheter Mitral Valve Repair for Degenerative Mitral Regurgitation
10.1001/jama.2023.7089 · 2023 · External reference
Catheter ablation of atrial fibrillation in patients with heart failure: Insights from the NCDR atrial fibrillation ablation registry
10.1016/j.hrthm.2025.06.048 · 2026 · External reference
Patterns of referral and postdischarge utilization of cardiac rehabilitation among patients hospitalized with heart failure: an analysis from the GWTG-HF registry
10.1161/circheartfailure.122.010144 · 2023 · External reference
Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure
10.1016/j.jchf.2021.02.006 · 2021 · External reference
Cardiac rehabilitation and readmissions after heart transplantation
10.1016/j.healun.2017.05.017 · 2018 · External reference
Tracking Cardiac Rehabilitation Utilization in Medicare Beneficiaries: 2017 UPDATE
10.1097/hcr.0000000000000675 · 2022 · External reference
The Society of Thoracic Surgeons Intermacs 2025 Annual Report: Focus on Outcomes in Older Adults
10.1016/j.athoracsur.2025.10.005 · 2026 · External reference
OPTN/SRTR 2023 Annual Data Report: Heart
10.1016/j.ajt.2025.01.024 · 2025 · External reference
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation
10.1016/j.healun.2025.04.014 · 2025 · External reference
Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association
10.1161/cir.0000000000001258 · 2024 · External reference
Forecasting the burden of cardiovascular disease and stroke in the United States through 2050-prevalence of risk factors and disease: a presidential advisory from the American Heart Association
10.1161/cir.0000000000001256 · 2024 · External reference
Expenditure on Heart Failure in the United States: The Medical Expenditure Panel Survey 2009-2018
10.1016/j.jchf.2022.05.006 · 2022 · External reference
Making heart failure count
10.1002/ejhf.2148 · 2021 · External reference
Accuracy of Self-Reported Heart Failure. The Atherosclerosis Risk in Communities (ARIC) Study
10.1016/j.cardfail.2017.09.002 · 2017 · External reference
Economic issues in heart failure in the United States
10.1016/j.cardfail.2021.12.017 · 2022 · External reference
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines
10.1016/j.jacc.2014.03.016 · 2014 · External reference
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement)
10.1016/j.jacc.2025.05.009 · 2026 · External reference
The economics of heart failure care
10.1016/j.pcad.2024.01.010 · 2024 · External reference
Incremental cost-effectiveness of guideline-directed medical therapies for heart failure
10.1016/j.jacc.2012.12.022 · 2013 · External reference
Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction
10.1001/jamacardio.2016.1747 · 2016 · External reference
Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction
10.1016/j.jchf.2016.02.007 · 2016 · External reference
Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction
10.7326/m16-0057 · 2016 · External reference
Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction
10.1001/jamanetworkopen.2021.14501 · 2021 · External reference
Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction
10.1001/jamacardio.2021.1437 · 2021 · External reference
Economic Modeling Analysis of an Intensive GDMT Optimization Program in Hospitalized Heart Failure Patients
10.1161/circheartfailure.123.011218 · 2023 · External reference
Cost-effectiveness of quadruple therapy in management of heart failure with reduced ejection fraction in the United States
10.1161/circoutcomes.122.009793 · 2023 · External reference
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction
10.1001/jamacardio.2023.0077 · 2023 · External reference
Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction
10.1001/jamainternmed.2022.5010 · 2022 · External reference
Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
10.1016/j.jchf.2024.03.006 · 2024 · External reference
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
10.1161/circulationaha.119.045093 · 2020 · External reference
Cost-effectiveness of coronary artery bypass surgery versus medicine in ischemic cardiomyopathy: the STICH randomized clinical trial
10.1161/circulationaha.121.056276 · 2022 · External reference
The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II
10.1016/j.jacc.2006.03.032 · 2006 · External reference
Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: results from the COAPT trial
10.1161/circulationaha.119.043275 · 2019 · External reference
Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)
10.1161/circulationaha.123.064527 · 2023 · External reference
10.1056/nejmra2312086
10.1056/nejmra2312086 · 2026 · External reference
Criteria for Defining Stages of Cardiogenic Shock Severity
10.1016/j.jacc.2022.04.049 · 2022 · External reference
Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry
10.1161/circoutcomes.123.010614 · 2024 · External reference
Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions
2024 · External reference
Fifteen-Year Trends in Incidence of Cardiogenic Shock Hospitalization and In-Hospital Mortality in the United States
10.1161/jaha.121.021061 · 2021 · External reference
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee
10.1016/j.jacc.2025.02.018 · 2025 · External reference
Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock
10.1016/j.jchf.2022.10.002 · 2023 · External reference
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes
2022 · External reference
Cardiogenic Shock Survivorship: A Multidisciplinary Approach Across the Continuum of Care
10.1016/j.jacc.2026.02.5080 · 2026 · External reference
Mortality trends related to cardiogenic shock in heart failure patients aged 25 and older across the United States: A study utilizing the CDC WONDER database from 1999 to 2023
2025 · External reference
Trends in Mortality Among Adults With Acute Myocardial Infarction With Cardiogenic Shock in the United States, 1999-2023
2025 · External reference
Clinical Course of Patients in Cardiogenic Shock Stratified by Phenotype
10.1016/j.jchf.2023.05.007 · 2023 · External reference
Impact of Age on Outcomes in Patients With Cardiogenic Shock
10.3389/fcvm.2021.688098 · 2021 · External reference
Cardiogenic Shock in Older Adults: A Focus on Age-Associated Risks and Approach to Management: A Scientific Statement From the American Heart Association
10.1161/cir.0000000000001214 · 2024 · External reference
Impact of Female Sex on Cardiogenic Shock Outcomes: A Cardiogenic Shock Working Group Report
10.1016/j.jchf.2023.09.025 · 2023 · External reference
Sex-Specific Transfer Outcomes in Patients With Non-Acute Myocardial Infarction-Related Cardiogenic Shock
10.1016/j.jchf.2025.102620 · 2025 · External reference
Sex differences in treatments and outcomes of patients with cardiogenic shock: a systematic review and epidemiological meta-analysis
10.1186/s13054-024-04973-5 · 2024 · External reference
Racial, Ethnic, Socioeconomic, and Geographic Inequities in Access to Mechanical Circulatory Support
2024 · External reference
Racial, Ethnic, and Sex Disparities in Patients With STEMI and Cardiogenic Shock
10.1016/j.jcin.2021.01.003 · 2021 · External reference
Racial and Ethnic Disparities in the Trends and Outcomes of Cardiogenic Shock Complicating Peripartum Cardiomyopathy
10.1001/jamanetworkopen.2022.20937 · 2022 · External reference
Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
10.1001/jamanetworkopen.2020.37748 · 2021 · External reference
Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group
10.1016/j.healun.2025.08.010 · 2026 · External reference
Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group
10.1016/j.healun.2024.05.015 · 2024 · External reference
Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group
10.1016/j.healun.2025.07.016 · 2025 · External reference
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams
10.1016/j.jacc.2021.07.044 · 2021 · External reference
Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock
10.1161/jaha.114.001462 · 2015 · External reference
A Standardized and Regionalized Network of Care for Cardiogenic Shock
10.1016/j.jchf.2022.04.004 · 2022 · External reference
Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States
10.1161/circheartfailure.119.006661 · 2020 · External reference
Cancer statistics, 2025
2025 · External reference
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions: A Scientific Statement From the American Heart Association
10.1161/cir.0b013e3182a88099 · 2013 · External reference
Modifiable Risk Factors and Major Cardiac Events Among Adult Survivors of Childhood Cancer
10.1200/jco.2013.49.3205 · 2013 · External reference
Risk Factors for Heart Failure Among Pan-European Childhood Cancer Survivors: A PanCareSurFup and ProCardio Cohort and Nested Case-Control Study
10.1200/jco.21.02944 · 2023 · External reference
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
10.1136/bmj.b4606 · 2009 · External reference
Clinical Care for People Who Survive Childhood Cancer: A Review
10.1001/jama.2023.16875 · 2023 · External reference
Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer
10.1200/jco.20.00418 · 2020 · External reference
Risk of Incident Heart Failure Among Young Adult Cancer Survivors
2023 · External reference
Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment
2025 · External reference
Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis
10.1136/heartjnl-2024-324301 · 2024 · External reference
Cardiovascular Disease Risk Among Cancer Survivors
10.1016/j.jacc.2022.04.042 · 2022 · External reference
Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases
10.1016/s0140-6736(19)31674-5 · 2019 · External reference
Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors
2022 · External reference
Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010
10.1001/jamanetworkopen.2022.54669 · 2023 · External reference
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
10.1200/jco.21.01736 · 2022 · External reference
Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors
10.1093/jnci/djae107 · 2024 · External reference
Anthracycline Cardiotoxicity in Adult Cancer Patients
2024 · External reference
Characteristics and Outcomes of Patients with Heart Failure and History of Malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register
10.1002/ejhf.3775 · 2025 · External reference
National Outcomes in Hospitalized Patients With Cancer and Comorbid Heart Failure
10.1016/j.cardfail.2019.02.007 · 2019 · External reference
Thirty-day hospital readmission in females with acute heart failure and breast cancer: A retrospective cohort study from national readmission database. Lazzeri C
10.1371/journal.pone.0301596 · 2024 · External reference
Characteristics and Outcomes of Patients with Cancer Hospitalized with New Onset Acute Heart Failure
10.1002/ehf2.14907 · 2025 · External reference
Patient Mortality Following New-Onset Heart Failure Stratified by Cancer Type and Status
10.1002/ejhf.2984 · 2023 · External reference
Heart Failure in Pregnant Women: A Concern Across the Pregnancy Continuum
10.1161/circheartfailure.117.004005 · 2018 · External reference
Prevalence of heart diseases in pregnant women referred to the heart diseases clinic for obstetrics
2018 · External reference
Peripartum Cardiomyopathy: JACC State-of-the-Art Review
10.1016/j.jacc.2019.11.014 · 2020 · External reference
Cardiomyopathy Prevalence and Pregnancy-Related Mortality: United States, 2010 to 2020
10.1016/j.jacadv.2025.101692 · 2025 · External reference
Risk Factors for Peripartum Cardiomyopathy: A Systematic Review and Meta-Analysis
10.1016/j.hlc.2025.03.010 · 2025 · External reference
Trends in Characteristics and Outcomes of Peripartum Cardiomyopathy Hospitalizations in the United States Between 2004 and 2018
10.1016/j.amjcard.2021.12.034 · 2022 · External reference
A 20-year population study of peripartum cardiomyopathy
10.1093/eurheartj/ehad626 · 2023 · External reference
Peripartum Cardiomyopathy: JACC State-of-the-Art Review
10.1016/j.jacc.2019.11.014 · 2020 · External reference
Optimization of Postpartum Care for Patients With and at Risk for Premature and Long-Term Cardiovascular Disease: 2026 ACC Expert Consensus Decision Pathway
10.1016/j.jacc.2025.11.001 · 2026 · External reference
Impact of Pregnancy on Mortality in Dilated Cardiomyopathy: Immediate and 12-Month Postpartum Outcomes: Data From the InCor Pregnancy and Heart Disease Registry
2026 · External reference
Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)
10.1016/j.jacc.2015.06.1309 · 2015 · External reference
Clinical Outcomes in Peripartum Cardiomyopathy Complicated by Cardiogenic Shock: A Retrospective Multicenter Cohort Study
10.1016/j.amjcard.2025.11.004 · 2026 · External reference
Long-term outcomes in peripartum cardiomyopathy
10.2174/1874192401913010013 · 2019 · External reference
Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
10.1016/j.jacc.2021.08.039 · 2021 · External reference
Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy
10.1161/circulationaha.119.037661 · 2020 · External reference
Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population
2022 · External reference
Familial Dilated Cardiomyopathy Caused by an Alpha-Tropomyosin Mutation
10.1016/j.jacc.2009.11.017 · 2010 · External reference
Clinical Features and Outcomes of Pediatric MYH7 -Related Dilated Cardiomyopathy
10.1161/jaha.124.036208 · 2024 · External reference
Clinical Phenotype and Genotype Associations With Improvement in Left Ventricular Function in Dilated Cardiomyopathy
2018 · External reference
Dynamic Ejection Fraction Trajectory in Patients With Dilated Cardiomyopathy With a Truncating Titin Variant
2022 · External reference
The response to cardiac resynchronization therapy in LMNA cardiomyopathy
10.1002/ejhf.2463 · 2022 · External reference
Atrial Fibrillation and Systemic Embolic Events in Patients With LMNA Cardiomyopathy
10.1016/j.jacc.2025.05.039 · 2025 · External reference
Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies
10.1161/circulationaha.118.039410 · 2019 · External reference
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers
10.1093/eurheartj/ehae409 · 2024 · External reference
Arrhythmic Risk Stratification of Carriers of Filamin C Truncating Variants
10.1001/jamacardio.2024.5543 · 2025 · External reference
Association of Pathogenic/Likely Pathogenic Genetic Variants for Cardiomyopathies With Clinical Outcomes: A Multiancestry Analysis in the All of Us Research Program
2025 · External reference
Arrhythmogenic Right Ventricular Cardiomyopathy
10.1056/nejmra1509267 · 2017 · External reference
Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria
10.1161/circulationaha.108.840827 · 2010 · External reference
International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework
2021 · External reference
Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis
2022 · External reference
Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers
10.1016/j.jacc.2013.06.033 · 2013 · External reference
Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
2017 · External reference
Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Study
10.1161/circulationaha.122.060866 · 2022 · External reference
Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration
2021 · External reference
A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
10.1093/eurheartj/ehac180 · 2022 · External reference
Genetic Spectrum of Idiopathic Restrictive Cardiomyopathy Uncovered by Next-Generation Sequencing
10.1371/journal.pone.0163362 · 2016 · External reference
Evidence-Based Assessment of Genes in Dilated Cardiomyopathy
10.1161/circulationaha.120.053033 · 2021 · External reference
Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy
10.1161/circulationaha.119.044934 · 2020 · External reference
To screen or not to screen for transthyretin cardiac amyloidosis
10.1016/j.nuclcard.2024.102122 · 2025 · External reference
Temporal Trends In The Incidence And Prevalence Of Transthyretin Amyloid Cardiomyopathy In The USA: An Observational Database Study
10.1016/j.cardfail.2024.10.223 · 2025 · External reference
Unresolved reference
External reference
Looking beyond left ventricular wall thickness: the search for cardiac amyloidosis in women
10.1080/13506129.2025.2562864 · 2025 · External reference
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
10.1002/ejhf.2646 · 2022 · External reference
Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathy
10.1080/13506129.2025.2507921 · 2025 · External reference
Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study
10.1161/jaha.125.042530 · 2025 · External reference
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
10.1016/j.jacc.2025.09.004 · 2026 · External reference
Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review
10.1161/circgen.121.003356 · 2021 · External reference
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population
10.1001/jamacardio.2024.2190 · 2024 · External reference
Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure
10.1001/jamacardio.2025.2948 · 2025 · External reference
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
10.1056/nejmoa1805689 · 2018 · External reference
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
10.1016/j.jacc.2024.11.042 · 2025 · External reference
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
10.1056/nejmoa2305434 · 2024 · External reference
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy
10.1016/j.jacc.2025.04.008 · 2025 · External reference
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
10.1056/nejmoa2409134 · 2025 · External reference
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy
2025 · External reference
Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis
10.1007/s12170-021-00670-y · 2021 · External reference
Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era
10.3389/fcvm.2021.765876 · 2022 · External reference
Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023
2026 · External reference
How common is hypertrophic cardiomyopathy… really?: Disease prevalence revisited 27 years after CARDIA
10.1016/j.ijcard.2023.04.005 · 2023 · External reference
Clinical Course and Management of Hypertrophic Cardiomyopathy. Longo DL
10.1056/nejmra1710575 · 2018 · External reference
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
10.1161/circulationaha.117.033200 · 2018 · External reference
Characteristics and Long-Term Outcomes of Asymptomatic Patients With Hypertrophic Cardiomyopathy
10.1016/j.jacc.2025.08.013 · 2025 · External reference
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
10.1016/j.jacc.2024.02.014 · 2024 · External reference
Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
10.1016/j.jacep.2022.07.012 · 2022 · External reference
Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies
10.1016/j.jacc.2015.02.061 · 2015 · External reference
Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID-19 Pandemic
10.1161/jaha.124.037047 · 2025 · External reference
Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
10.1161/circulationaha.119.044366 · 2020 · External reference
Atrial Fibrillation in Hypertrophic Cardiomyopathy
2024 · External reference
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
10.1161/jaha.124.038758 · 2025 · External reference
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee
10.1016/j.cardfail.2019.03.007 · 2019 · External reference
Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association
10.1161/cir.0000000000001405 · 2026 · External reference
Controversies and Conundrums in Cardiac Cachexia: Key Questions About Wasting in Patients With HFrEF
10.1016/j.jchf.2024.03.003 · 2024 · External reference
Nutrition Assessment and Dietary Interventions in Heart Failure: JACC Review Topic of the Week
10.1016/j.jacc.2022.02.025 · 2022 · External reference
Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition)
10.1177/0148607112440285 · 2012 · External reference
Potential association with malnutrition and allocation of combination medical therapies in hospitalized heart failure patients with reduced ejection fraction
10.1038/s41598-022-12357-4 · 2022 · External reference
Prevalence and prognostic implications of malnutrition as defined by GLIM criteria in elderly patients with heart failure
10.1016/j.clnu.2021.01.014 · 2021 · External reference
The controlling nutritional status score predicts outcomes of cardiovascular events in patients with heart failure with preserved ejection fraction
10.1016/j.ijcha.2020.100563 · 2020 · External reference
Prevalence of malnutrition and its association with outcomes in heart failure: A systematic review and meta-analysis
10.1016/j.nut.2025.112913 · 2025 · External reference
Prognostic Significance of Nutritional Scores in Patients With Heart Failure: Insights From the PARAGON-HF Trial
10.1161/jaha.124.038872 · 2025 · External reference
Impact of Malnutrition on the Outcomes in Patients Admitted with Heart Failure
10.3390/jcm13144215 · 2024 · External reference
Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction
2019 · External reference
Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation
10.1016/j.jacc.2023.04.047 · 2023 · External reference
Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure
2018 · External reference
The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper
10.1002/ncp.10588 · 2021 · External reference
Exploring the prevalence, impact and experience of cardiac cachexia in patients with advanced heart failure and their caregivers: A sequential phased study
10.1177/02692163221101748 · 2022 · External reference
Prognostic impact of cachexia by multi-assessment in older adults with heart failure: FRAGILE-HF cohort study
10.1002/jcsm.13291 · 2023 · External reference
Growth Differentiation Factor–15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure
2025 · External reference
Cardiac Cachexia in Left Ventricular Assist Device Recipients and the Implications of Weight Gain Early After Implantation
10.1161/jaha.122.029086 · 2023 · External reference
Cachexia Is Associated With Adverse Outcomes in Patients Admitted With Heart Failure
10.1016/j.amjcard.2022.10.017 · 2023 · External reference
Prognostic Impact and Prevalence of Cachexia in Patients With Heart Failure: A Systematic Review and Meta-Analysis
10.1002/jcsm.13596 · 2024 · External reference
Wasting as independent risk factor for mortality in chronic heart failure
10.1016/s0140-6736(96)07015-8 · 1997 · External reference
Cachexia: a new definition
10.1016/j.clnu.2008.06.013 · 2008 · External reference
Prevalence, Characteristics, and Prognostic Associations of Cachexia Diagnosed Using Asian Working Group for Cachexia 2023 Criteria in Older Adults With Heart Failure
10.1253/circj.cj-24-0805 · 2025 · External reference
BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study
10.1016/j.ijcard.2017.01.130 · 2017 · External reference
Association between body mass index and prognosis of patients hospitalized with heart failure
10.1038/s41598-020-73640-w · 2020 · External reference
Body mass index and survival in people with heart failure
10.1136/heartjnl-2023-322459 · 2023 · External reference
Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction
10.1093/eurjpc/zwaa117 · 2021 · External reference
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)
10.1093/eurheartj/ehs381 · 2013 · External reference
Muscle wasting in young patients with dilated cardiomyopathy
10.1002/jcsm.12193 · 2017 · External reference
Sarcopenia: revised European consensus on definition and diagnosis
10.1093/ageing/afy169 · 2019 · External reference
Sarcopenia in Heart Failure: A Systematic Review and Meta-Analysis
10.1002/ehf2.13255 · 2021 · External reference
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure
2022 · External reference
Muscle wasting as an independent predictor of survival in patients with chronic heart failure
10.1002/jcsm.12603 · 2020 · External reference
Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement
10.1016/j.jacc.2023.01.049 · 2023 · External reference
Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future
10.1016/j.jacc.2018.02.059 · 2018 · External reference
Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study
10.1016/s2214-109x(23)00408-4 · 2023 · External reference
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction
10.1161/circheartfailure.124.011598 · 2025 · External reference
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE
10.1002/ejhf.2856 · 2023 · External reference
Association Between Functional Impairment and Medication Burden in Adults with Heart Failure
10.1111/jgs.15654 · 2019 · External reference
Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES)
10.1186/s12872-019-1058-7 · 2019 · External reference
Polypharmacy in Older Adults Hospitalized for Heart Failure
10.1161/circheartfailure.120.006977 · 2020 · External reference
Prevalence of malnutrition and its association with outcomes in heart failure: A systematic review and meta-analysis
2025 · External reference
Patterns of Prevalence of Multiple Sensory Impairments Among Community-dwelling Older Adults
10.1093/gerona/glab294 · 2022 · External reference
The prevalence of frailty in heart failure: A systematic review and meta-analysis
10.1016/j.ijcard.2017.01.153 · 2017 · External reference
Frailty Is Intertwined With Heart Failure
2019 · External reference
Severity of mobility limitation and adverse outcomes in heart failure
2025 · External reference
Preventing and Managing Falls in Adults With Cardiovascular Disease: A Scientific Statement From the American Heart Association
10.1161/hcq.0000000000000108 · 2022 · External reference
Cognitive Impairment in Heart Failure: A Heart Failure Society of America Scientific Statement
10.1016/j.cardfail.2024.01.003 · 2024 · External reference
Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure
10.1016/j.cardfail.2020.09.007 · 2021 · External reference
Depression in hospitalized older patients with congestive heart failure
10.1016/s0163-8343(98)80001-7 · 1998 · External reference
Depression in Community-Dwelling Elderly Patients With Heart Failure
10.1016/j.apnu.2017.11.010 · 2018 · External reference
Depression and Heart Failure: The Lonely Comorbidity
10.1002/ejhf.1865 · 2020 · External reference
Depression after heart failure and risk of cardiovascular and all-cause mortality: A meta-analysis
10.1016/j.ypmed.2014.03.007 · 2014 · External reference
Depression predicts mortality and hospitalization in heart failure: A six-years follow-up study
10.1016/j.jad.2016.05.024 · 2016 · External reference
Depressive symptoms and risk of functional decline and death in patients with heart failure
10.1016/s0735-1097(01)01334-1 · 2001 · External reference
Major Depression and Long-Term Survival of Patients With Heart Failure
10.1097/psy.0000000000000346 · 2016 · External reference
Depression and Health Status in Elderly Patients With Heart Failure: A 6-Month Prospective Study in Primary Care
10.1111/j.1076-7460.2004.03072.x · 2004 · External reference
The impact of perceived and objective social isolation on hospital readmission in patients with heart failure: A systematic review and meta-analysis of observational studies
10.1016/j.genhosppsych.2019.07.002 · 2019 · External reference
Perceived Social Isolation and Outcomes in Patients With Heart Failure
10.1161/jaha.117.008069 · 2018 · External reference
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
2023 · External reference
The association between beta-blockers and outcomes in patients with heart failure and concurrent Alzheimer’s disease and related dementias
10.1111/jgs.18086 · 2023 · External reference
Efficacy and Safety of Heart Failure Treatment According to Frailty Status: A Systematic Review
10.1161/jaha.125.042367 · 2025 · External reference
Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure, 2000-2007
10.1001/archinternmed.2010.371 · 2011 · External reference
Care in the Last Year of Life for Community Patients With Heart Failure
2015 · External reference
Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life
10.18553/jmcp.2016.22.12.1446 · 2016 · External reference
Temporal Trends and Sex Differences in Intensity of Healthcare at the End of Life in Adults With Heart Failure
10.1161/jaha.120.018495 · 2021 · External reference
Advance Care Planning and End-of-Life Education in Heart Failure: Insights From the NCDR PINNACLE Registry
10.1161/circoutcomes.122.008989 · 2023 · External reference
Trends in time in the management of the implantable cardioverter defibrillator in the last phase of life: a retrospective study of medical records
10.1177/1474515119844660 · 2019 · External reference
The implantable cardioverter-defibrillators at the end of life: a double-edged sword of a life-saving technology
10.1016/j.tcm.2025.09.005 · 2026 · External reference
Palliative Care in Heart Failure
10.1016/j.jacc.2017.05.030 · 2017 · External reference
Association of Palliative Care Intervention With Health Care Use, Symptom Burden and Advance Care Planning in Adults With Heart Failure and Other Noncancer Chronic Illness
10.1016/j.jpainsymman.2021.02.017 · 2021 · External reference
Palliative Care Consultation Reduces Heart Failure Transitions: A Matched Analysis
10.1161/jaha.119.013989 · 2020 · External reference
Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER : a randomized controlled study
10.1002/ejhf.151 · 2014 · External reference
The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial
10.1016/j.cardfail.2021.02.019 · 2021 · External reference
Incidence and Trends in the Use of Palliative Care among Patients with Reduced, Middle-Range, and Preserved Ejection Fraction Heart Failure
10.1089/jpm.2022.0093 · 2022 · External reference
Palliative Care Referral among Patients Hospitalized with Advanced Heart Failure
10.1089/jpm.2013.0658 · 2014 · External reference
Quality of End-of-Life Care Provided to Patients With Different Serious Illnesses
10.1001/jamainternmed.2016.1200 · 2016 · External reference
Characteristics and Trends Among Patients With Cardiovascular Disease Referred to Palliative Care
10.1001/jamanetworkopen.2019.2375 · 2019 · External reference
Palliative Care Utilization in Patients With Heart Failure With Preserved Ejection Fraction
2024 · External reference
Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines–Heart Failure Registry
10.1001/jamacardio.2018.2678 · 2018 · External reference
Where Adults With Heart Failure Die: Insights From the CDC-WONDER Database
2025 · External reference
Geographic Distribution of Advanced Heart Failure and Transplant Cardiologists in the United States
10.1016/j.yjcafi.2026.03.004 · 2026 · External reference
Match Decline Forecasts Slowing Advanced Heart Failure Cardiology Workforce Growth Toward 2030
10.1016/j.cardfail.2025.08.022 · 2025 · External reference
Interest in Advanced Heart Failure and Transplant Cardiology Fellowship
2024 · External reference
10.1016/j.cardfail.2026.07.005
10.1016/j.cardfail.2026.07.005 · External reference
The AHFTC Fellowship Match in an Era of Declining Interest
2026 · External reference
The HFSA Advanced Heart Failure and Transplant Cardiology Fellowship Consensus Conference
10.1016/j.cardfail.2023.09.007 · 2024 · External reference
Effectiveness of the Advanced Practice Nursing interventions in the patient with heart failure: A systematic review
10.1002/nop2.847 · 2021 · External reference
Effectiveness of the Pharmacist-Involved Multidisciplinary Management of Heart Failure to Improve Hospitalizations and Mortality Rates in 4630 Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
10.1016/j.cardfail.2019.07.455 · 2019 · External reference
Clinical Pharmacy Services in Heart Failure: An Opinion Paper From the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network
10.1016/j.cardfail.2013.02.002 · 2013 · External reference
Randomised controlled trial of specialist nurse intervention in heart failure
10.1136/bmj.323.7315.715 · 2001 · External reference
Increasing the heart failure nursing workforce: recommendations by the British Society for Heart Failure Nurse Forum
10.12968/bjca.2019.0109 · 2019 · External reference
Heart Failure Training for the Internist
2024 · External reference
